Literature DB >> 28566369

T Cell-Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide of Streptococcus pneumoniae.

Dustin R Middleton1, Lina Sun1, Amy V Paschall1, Fikri Y Avci2.   

Abstract

Most pathogenic bacteria express surface carbohydrates called capsular polysaccharides (CPSs). CPSs are important vaccine targets because they are easily accessible and recognizable by the immune system. However, CPS-specific adaptive humoral immune responses can only be achieved by the covalent conjugation of CPSs with carrier proteins to produce glycoconjugate vaccines. We previously described a mechanism by which a model glycoconjugate vaccine can activate the adaptive immune system and demonstrated that the mammalian CD4+ T cell repertoire contains a population of carbohydrate-specific T cells. In this study, we use glycoconjugates of type 3 Streptococcus pneumoniae CPS (Pn3P) to assess whether the carbohydrate-specific adaptive immune response exemplified in our previous study can be applied to the conjugates of this lethal pathogen. In this article, we provide evidence for the functional roles of Pn3P-specific CD4+ T cells utilizing mouse immunization schemes that induce Pn3P-specific IgG responses in a carbohydrate-specific T cell-dependent manner.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28566369      PMCID: PMC5515494          DOI: 10.4049/jimmunol.1700026

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.

Authors:  Ron Dagan; Scott Patterson; Christine Juergens; David Greenberg; Noga Givon-Lavi; Nurith Porat; Alejandra Gurtman; William C Gruber; Daniel A Scott
Journal:  Clin Infect Dis       Date:  2013-06-26       Impact factor: 9.079

2.  Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Authors:  Walter H B Demczuk; Irene Martin; Averil Griffith; Brigitte Lefebvre; Allison McGeer; Marguerite Lovgren; Gregory J Tyrrell; Shalini Desai; Lindsey Sherrard; Heather Adam; Matthew Gilmour; George G Zhanel
Journal:  Can J Microbiol       Date:  2013-10-21       Impact factor: 2.419

3.  Healthcare utilization and cost of pneumococcal disease in the United States.

Authors:  Susan S Huang; Kristen M Johnson; G Thomas Ray; Peter Wroe; Tracy A Lieu; Matthew R Moore; Elizabeth R Zell; Jeffrey A Linder; Carlos G Grijalva; Joshua P Metlay; Jonathan A Finkelstein
Journal:  Vaccine       Date:  2011-03-11       Impact factor: 3.641

Review 4.  How bacterial carbohydrates influence the adaptive immune system.

Authors:  Fikri Y Avci; Dennis L Kasper
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 5.  Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease.

Authors:  W P Hausdorff; R Dagan; F Beckers; L Schuerman
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

6.  Immunization with meningococcal polysaccharide-tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice.

Authors:  Subramanian Muthukkumar; Kathryn E Stein
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

7.  T cells control the generation of nanomolar-affinity anti-glycan antibodies.

Authors:  Zinaida Polonskaya; Shenglou Deng; Anita Sarkar; Lisa Kain; Marta Comellas-Aragones; Craig S McKay; Katarzyna Kaczanowska; Marie Holt; Ryan McBride; Valle Palomo; Kevin M Self; Seth Taylor; Adriana Irimia; Sanjay R Mehta; Jennifer M Dan; Matthew Brigger; Shane Crotty; Stephen P Schoenberger; James C Paulson; Ian A Wilson; Paul B Savage; M G Finn; Luc Teyton
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

Review 8.  Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.

Authors:  William C Gruber; Daniel A Scott; Emilio A Emini
Journal:  Ann N Y Acad Sci       Date:  2012-07-25       Impact factor: 5.691

Review 9.  Carbohydrates and T cells: a sweet twosome.

Authors:  Fikri Y Avci; Xiangming Li; Moriya Tsuji; Dennis L Kasper
Journal:  Semin Immunol       Date:  2013-06-10       Impact factor: 11.130

10.  PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES.

Authors:  C M Macleod; R G Hodges; M Heidelberger; W G Bernhard
Journal:  J Exp Med       Date:  1945-11-30       Impact factor: 14.307

View more
  15 in total

1.  Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines.

Authors:  Ximei Sun; Giuseppe Stefanetti; Francesco Berti; Dennis L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

2.  On the mechanisms of conjugate vaccines.

Authors:  Rino Rappuoli; Ennio De Gregorio; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-21       Impact factor: 11.205

3.  Isolation and characterization of new human carrier peptides from two important vaccine immunogens.

Authors:  Paeton L Wantuch; Lina Sun; Rachel K LoPilato; Jarrod J Mousa; Robert S Haltiwanger; Fikri Y Avci
Journal:  Vaccine       Date:  2020-01-28       Impact factor: 3.641

4.  Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.

Authors:  Sarah Sterrett; Binghao J Peng; Robert L Burton; David C LaFon; Andrew O Westfall; Suddham Singh; Michael Pride; Annaliesa S Anderson; Gregory C Ippolito; Harry W Schroeder; Moon H Nahm; A Krishna Prasad; Paul Goepfert; Anju Bansal
Journal:  Vaccine       Date:  2020-01-03       Impact factor: 3.641

Review 5.  Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections.

Authors:  Jan T Poolman
Journal:  NPJ Vaccines       Date:  2020-09-11       Impact factor: 7.344

6.  Invasive pneumococcal disease in relation to vaccine type serotypes.

Authors:  Paeton L Wantuch; Fikri Y Avci
Journal:  Hum Vaccin Immunother       Date:  2019-02-20       Impact factor: 3.452

7.  Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help.

Authors:  Lina Sun; Amy V Paschall; Dustin R Middleton; Mayumi Ishihara; Ahmet Ozdilek; Paeton L Wantuch; Javid Aceil; Jeremy A Duke; Celia C LaBranche; Michael Tiemeyer; Fikri Y Avci
Journal:  Nat Commun       Date:  2020-05-21       Impact factor: 14.919

8.  Enzymatic Hydrolysis of Pneumococcal Capsular Polysaccharide Renders the Bacterium Vulnerable to Host Defense.

Authors:  Dustin R Middleton; Amy V Paschall; Jeremy A Duke; Fikri Y Avci
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

9.  A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.

Authors:  Ahmet Ozdilek; Jiachen Huang; Rachelle Babb; Amy V Paschall; Dustin R Middleton; Jeremy A Duke; Liise-Anne Pirofski; Jarrod J Mousa; Fikri Y Avci
Journal:  mBio       Date:  2021-06-01       Impact factor: 7.867

Review 10.  Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them.

Authors:  Paeton L Wantuch; Fikri Y Avci
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.